We invest in the technologies of tomorrow.
Esco Ventures invests in life science startups and is also engaged in venture creation to discover and develop technologies addressing large unmet medical needs. Our companies are collaborating with leading academic institutions, hospitals and clinicians around the world to discover and develop these technologies.
Carmentix is an Esco Ventures X founded startup company developing a novel biomarker prognostic panel for preterm birth. Carmentix is determined to significantly reduce the number of preterm birth in the global setting by establishing biomolecular tools that will alert clinicians for the risk of preterm birth weeks before symptoms occur.
Carmine Therapeutics is an Esco Ventures X company pioneering a powerful new class of drugs based on engineered red blood cells extracellular vesicles (RBCEVs), founded by Esco Ventures and Professors Harvey Lodish, Minh Le and Jiahai Shi.
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation to proof-of-concept (Phase II Clinical Trials).
Maiden Therapeutics is an Esco Ventures X founded drug discovery platform company unleashing the power of the human milk microbiome. From bugs to drugs, Maiden Therapeutics generates molecules targeting many disease indications.
Medical Plast develops and manufactures proprietary high value medical consumables and reagents.
Using innovative and proprietary technology, Nanoview Biosciences is striving to become the leader in exosomes analysis for basic research, therapeutics development and medical diagnostics